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Abstract
Genetic mutant organisms pervade all areas of Biology. Early on, herpesviruses (HV) were found to be amenable to
genetic analysis using homologous recombination techniques in eukaryotic cells. More recently, HV genomes
cloned onto a bacterial artificial chromosome (BAC) have become available. HV BACs can be easily modified in E.
coli and reintroduced in eukaryotic cells to produce infectious viruses. Mutants derived from HV BACs have been
used both to understand the functions of all types of genetic elements present on the virus genome, but also to
generate mutants with potentially medically relevant properties such as preventative vaccines. Here we retrace the
development of the BAC technology applied to the Epstein-Barr virus (EBV) and review the strategies available for
the construction of mutants. We expand on the appropriate controls required for proper use of the EBV BACs, and
on the technical hurdles researchers face in working with these recombinants. We then discuss how further tech-
nological developments might successfully overcome these difficulties. Finally, we catalog the EBV BAC mutants
that are currently available and illustrate their contributions to the field using a few representative examples.
Introduction
Genetics became an integral part of the Epstein-Barr
virus (EBV) research field at an early stage. Identifica-
tion of viral strains with unusual properties, e.g. incap-
able of initiating lytic replication, such as Raji, or of
transforming B cells, such as P3HR1, later coupled to
sequencing allowed the identification of genes or of a
group of genes likely to be involved in these functions
[1-3]. Although these early EBV mutants appeared spon-
taneously, they provided an important tool for EBV
research. More recently, strategies have been developed
to allow researchers to direct mutagenesis of the EBV
genome in order to design specific mutants of interest.
The ability to associate specific genes with unique
mutant phenotypes was an important step, however,
definitive evidence that such phenotypes are associated
with specific genes required the construction of rever-
tants. For example, proof that the P3HR1 phenotype
was caused by the loss of EBNA2 required the reintro-
duction of this gene back into the mutant genome
through transfection of an EBV DNA fragment that
spans the EBNA2 region and the observation that a suc-
cessfully recombined virus had regained its transforming
ability [4,5]. Not only did this observation define
EBNA2 as a key transforming gene, it also provided an
elegant method to select for recombinants from the
background of defective P3HR1 viruses. Indeed, lympho-
blastoid cell lines (LCL) generated with supernatants
from EBNA-2 transfected P3HR1 cells contained predo-
minantly, if not exclusively, recombinant viruses [4,5].
Therefore, the introduction of EBNA2 provided a potent
selection method that could be used to construct
mutant viruses. Recombination with a combination of
cosmid that contained EBNA2 and of overlapping cos-
mids that carried a mutated version of another EBV
gene, e.g. EBNA3, allowed the generation of EBV
mutants that had both re-acquired EBNA2 and incorpo-
rated the mutated gene [6]. This technology, based on
homologous recombination in eukaryotic cells, has pro-
ven invaluable for our understanding of EBV-driven B
cell transformation.
A related but distinct strategy for generating EBV
mutants consisted of exchanging a viral gene of interest
located on the EBV Akata genome with a selection mar-
ker such as neomycin [7]. Neomycin resistant Akata cell
clones must then be screened to identify those contain-
ing successfully recombined mutants. In a further step,
mutants often had to be purified from wild type EBV
genomes present in the same cell clones. This was
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of interest and subsequently exposing an EBV-negative
cell line to the supernatants from these cells. This was
performed at a low multiplicity of infection to ensure
that every newly infected cell would carry either the
mutant or the wild type viruses [7]. The B cell clones
would then be screened for the presence of the mutant
and selected for phenotypic characterization. This purifi-
cation step can only be performed if the mutant has
retained its ability to lytically replicate and to infect tar-
get cells from which they can be expanded. Therefore,
mutant viruses that lack the genetic elements essential
for either replication or infection cannot, in principle,
be obtained by this method. These limitations, com-
bined with the tedious sequential screening steps
required by this method, led to the development of a
quicker and more versatile strategy for the construction
of recombinant viruses [8].
This new method, known as HV BAC technology, was
developed in the late 1990 s in several laboratories in
Munich for murine cytomegalovirus, EBV, human cyto-
megalovirus, and murine gammaherpesvirus 68 [9-12].
Since then, several human and animal HV genomes,
including herpes simplex virus type 1 [13,26], varicella-
zoster virus [14], Kaposi’s sarcoma-associated herpes-
virus (KSHV) [15,16], rhesus cytomegalovirus [17], rhe-
sus rhadinovirus [18], pseudorabies virus [19],
herpesvirus saimiri [20], and Marek’s disease virus [21],
have been cloned as BACs.
The rationale of the HV BAC approach, which repre-
sented an abrupt change of tack from the conventional
views of the time, was to clone the complete HV gen-
omes as BACs in order to perform mutagenesis of the
viral genome in E.coli cells. In a prokaryotic context,
eukaryotic genes are not required for persistence of the
viral genome and can therefore be extensively modified
without any consequences for its maintenance. However,
DNA can only persist in bacterial cells if it carries a pro-
karyotic replicon. Therefore, a BAC flanked by HV-spe-
cific sequences was introduced into infected cell lines in
order to trigger homologous recombination. This was
achieved with great efficiency for alpha-and betaherpes-
viruses for which fully lytic cellular systems are available,
but proved to be a rather arduous task for gammaher-
pesviruses [10,15]. This might provide an explanation
for the fact that only two human KSHV BACs from two
different strains have been published [15,16], one of
which was obtained with great difficulty by our group,
and that only three EBV BACs from two strains have
been generated in the last 12 years [10,22,23]. In the
same vein, the generation time for EBV mutants is still
much longer than for those of alphaherpesvirus mutants.
This review will focus on EBV BAC technology and its
mechanics, before highlighting its use as a powerful
research tool using specific examples. Therefore, we
make no pretense of presenting an exhaustive summary
of EBV genetics in general but instead recommend ear-
lier references on that topic [24,25]. We have attempted
to catalog all EBV BAC recombinants available to date
(Table 1), but apologize in advance to colleagues whose
work might have slipped our attention.
Technical issues
Overview
The defining feature of EBV BAC technology is the abil-
ity to shuttle the recombinant viruses between prokaryo-
tic and eukaryotic backgrounds (Figure 1). As a plasmid
in E.coli, the EBV BACs can be easily modified using
t h eh i g h l yv e r s a t i l eg e n e t i ct o o l sd e v e l o p e di nt h e s e
cells. Foreign sequences can be added to the recombi-
nant viruses, as long as they stay within the constraints
imposed by the limits of the EBV capsid packaging
capacity. Examples are selection markers such as anti-
biotic resistance cassettes, genes encoding fluorescent
proteins, or tumor antigens. When using BAC technol-
ogy, extensive controls can be performed (see below),
including the possibility to generate revertants of the
mutated EBV BACs. All these techniques are very
powerful and not more complex than conventional
Molecular Biology cloning techniques.
The mutated EBV BAC is also a genuine virus, pro-
vided it is transferred back to a eukaryotic environment
in which the recombinant viral DNA can be packaged
into infectious virions. This obviously requires introduc-
tion of the EBV BAC DNA into cells that support lytic
replication. Furthermore, lytic replication must be easily
initiated in these cells, if possible in a physiological way,
e.g. through expression of the trans-activators BZLF1
and BRLF1. There are only a limited number of cell
lines that fulfil these conditions. Furthermore, we have
observed on many occasions that only a subset of clones
generated from a cell line transfected with the same
EBV BAC will sustain replication to a useful level. This
probably reflects the marked propensity of gammaher-
pesviruses to maintain tightly latent infection, at least in
vitro. This characteristic again contrasts with the relative
ease with which alpha-and betaherpesvirus BACs
undergo replication following transfection of the recom-
binant viral DNA into permissive cells [see for example
[11,13,26]]. Indeed, transfected alpha-HV genomes will
spontaneously initiate lytic replication and launch a first
round of virus production from which the infection can
be propagated to neighboring cells. Thus, the difficulty
associated with the generation of high-quality producer
cell lines is the current bottleneck of EBV BAC technol-
ogy with regards to gamma-HV applications. To add
insult to injury, some of these gamma-HV producer cell
lines tend to lose their ability to support lytic replication
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behind this phenomenon is unknown to us, but it neces-
sitates careful freezing of multiple aliquots of the cell
lines at an early time point. Despite these limitations,
we have never lost any producer cell line, and go back
to early passage freezing as soon as the replication rates
decline.
Available systems
T h r e er e c o m b i n a n tw i l d - t y p eE B V sh a v eb e e nc o n -
structed to date (Table 1) [10,22,23]. All of these were
constructed by insertion of the prokaryotic F-plasmid,
or F-factor, in either the B95.8 [10,23] or the Akata
strain [22]. The two B95.8 BACs differ in the site of the
F-plasmid insertion, either at the site of the B95.8 dele-
tion [10], or in the major internal repeat region [23]. In
the Akata BAC, the F-plasmid is inserted in the BXLF1
open reading frame that encodes the viral thymidine
kinase and was previously shown to be dispensable in
vitro [22]. The insertion site of the F-plasmid does not
affect the phenotype of the virus [10]. In all three con-
structs, eukaryotic and prokaryotic resistance cassettes
were inserted into the F-plasmid (hygromcin, neomycin
or puromycin and chloramphenicol or kanamycin,
respectively). The Akata BAC also contains a unique I-
PpoI restriction site, flanked by a SV40 enhancer/pro-
moter and a polyA site which allows conventional clon-
ing of genes to be expressed at high levels on the viral
recombinant [22]. It is interesting to note that all three
BACs were introduced into different cell lines. The
Akata BAC was re-introduced into EBV genome-nega-
tive Akata cells, one of the B95.8 BACs was introduced
into 293T cells [23] and the other into HEK293 or AGS
cells [10,27]. It is therefore possible to generate
Table 1 List of available EBV BACs
gene/locus protein function reference
wild-type B95.8 [10,23]
wild-type Akata [22]
BALF4 virus-cell fusion [43]
BFLF2 DNA packaging, nuclear egress [74]
BFRF1 nuclear egress [75]
BGLF4 protein kinase [38,76,77]
BGLF5 alkaline exonuclease, virus maturation [78]
BHRF1 anti-apoptotic [61]
BHRF1+BARF1 anti-apoptotic [61]
BLLF1 virus binding [42]
BMRF1 DNA polymerase processivity [79,80]
BMRF1+BALF5 DNA replication [80]
BNRF1 virus transport [81]
BNLF2a immune evasion [37]
BRLF1 lytic replication [47]
BZLF1 lytic replication [47]
BZLF1 promoter lytic replication [82]
EBNA1 episome maintenance, transactivation [59]
EBNA2 transformation, transactivation [83]
EBNA3A conditional
EBNA3A
transformation, transactivation [84]
[85]
EBNA3B unknown [23]
EBNA3C conditional
EBNA3C conditional †
transformation, transactivation [84]
[86]
LMP1 transformation, transactivation [87]
LMP2A membrane signal transduction, B cell survival [88]
oriLyt ZRE sites lytic replication [89]
CTCF binding site between oriP and Cp EBNA2 transcription [90]
snoRNA1 unknown [91]
terminal repeats DNA packaging [92]
†Akata strain
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cells. B95.8 virus production was initiated either by
introducing BZLF1 in the producer cell lines, alone or
in combination with BRLF1, or phorbol 12-myristate
13-acetate and n-butyrate. BZLF1 can be directly trans-
fected into 293 cells or delivered via infection with an
adenovirus vector. The Akata BAC virus can be induced
by crosslinking of surface immunoglobulins, as initially
developed for Akata cells [28].
Mutant generation
Two methods are mainly used to construct mutants of
the EBV BACs, both are based on homologous recombi-
nation between wild type and mutant versions of a gene
of interest [29] (Figure 2 and 3). Both methods require
the genetic elements to be exchanged to be flanked by
identical DNA sequences in order to initiate recombina-
tion. Thus the targeting vector consists of the mutated
gene flanked by sequences homologous to the viral gen-
ome. If ablation of a genetic element is required, its
flanking regions are simply juxtaposed.
One method makes use of linearized targeting vectors
to initiate recombination (Figure 2). In this case, as a
consequence, the wild type target gene will be excised
from the EBV BAC and the mutated versions of the
gene of interest inserted in its position. However, this
event is relatively rare, and strict selection methods
must be applied to successfully identify the properly
recombined EBV BACs. To this aim, an antibiotic
resistance cassette is inserted next to the mutated gene.
As a result, recombination not only exchanges the wild
type gene against its mutated version but also inserts
the antibiotic resistance cassette. This phenotypic mar-
ker can be flanked by Flp-recombinase target (frt) sites.
Transient transfection of the Flp recombinase into cells
that contain the EBV BAC then allows excision of the
antibiotic resistance cassette, leaving behind the mutated
gene and one Frt site.
Another method, dubbed ‘chromosomal building’, uses
circular targeting vectors carrying multiple selection
markers, an arabinose-inducible recA gene, and the
mutated version of the gene of interest, flanked by two
regions of homology that will determine the site of
homologous recombination (Figure 3). The selection
markers typically include a temperature-sensitive origin
of replication, an antibiotic resistance gene such as
ampicillin, and the lacZ gene. Upon transcription of
RecA, recombination is initiated and leads to fusion of
the targeting vector with the EBV BAC via one of the
regions of homology. This yields a co-integrate that car-
ries both the wild type and the mutated sequence, both
flanked by identical sequences from the EBV genome.
The co-integrate therefore carries two identical sets of
the flanking regions of homology. If the chlorampheni-
col resistance gene is present on the BAC then the co-
integrate can be selected for by growing the bacterial
cells in the presence of chloramphenicol and ampicillin,
which is present in the target vector. Shifting the cells
E.coli
selection
stable
transfection
Eukaryotic cell
lytic
 induction
Virus particles
 re-analysis of
BAC DNA
mutant
construction
EBV 
F-factor
EBV 
F-factor
Figure 1 The EBV BAC system: an overview. The cloned EBV-BAC can be manipulated in E.coli cells using multiple techniques that rely on
homologous recombination. The mutated EBV BAC is then introduced into 293 cells and selected with an antibiotic to create a producer cell
line from which infectious particles that contain the mutant EBV BAC can be produced. The episomes present in the producer cell line can be
extracted and reintroduced in E.coli where multiple controls such as restriction analyses, Southern blotting and sequencing, can be readily
performed.
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recombined targeting plasmids after a few cell divisions
due to the presence of the temperature-sensitive origin
of replication. Co-integrate formation can be easily
monitored by restriction enzyme digest and is usually
very efficient. Once co-integrate formation is con-
firmed, cells are then shifted back to arabinose-con-
taining medium at a permissive temperature to induce
recombination within the co-integrate. The EBV BAC
and the targeting vector can initiate recombination
through the region of homology located to the right or
left of the gene of interest and its mutated version in
order to form a co-integrate. Reciprocally, this co-inte-
grate can then be resolved through recombination of
either of the homologous flanking sequences, resulting
in the potential for two alternative plasmids to be gen-
erated during this process. If resolution of the co-inte-
grate takes place through the flanking region engaged
in the generation of the co-integrate, the mutated gene
remains on the targeting vector, and the EBV BAC
wild type sequence is reconstituted. In contrast, if
resolution occurs through recombination of the flank-
ing regions not used for construction of the co-inte-
grate, the targeting vector is recombined with the wild
type copy of the gene and the mutated EBV BAC is
generated. Finally, in order to induce the removal of
the targeting vector from the bacterial cells, cells are
propagated at non-permissive temperature. Clones can
then be assessed for the loss of lacZ and sensitivity to
ampicillin which is indicative of successful elimination
of the targeting vector. Candidate clones require
screening by restriction enzyme analysis, colony PCR
or any other appropriate technique.
The enzymes typically used for recombination are
either E.coli RecA or l-phage Red recombinase, used
alone or in combination with RecE and RecT from the
Rac prophage [30,31]. Both are very potent recombi-
nases and generation of co-integrates is usually straight-
forward. However, resolution of co-integrates does not
yield an equal percentage of wild type and mutant gen-
omes. Instead, the majority of resolved co-integrates will
be revertant wild type clones (from 51 to 98% in our
experience). More recently, positive/negative selection
methods using the galK gene or a combination of two
selection markers, such as kanamycin and streptomycin,
have also been reported [32,33]. A very efficient alterna-
tive positive/negative selection method combines Red
recombination and endonuclease I-SceI cleavage. In this
strategy, the positive selection marker that was used to
introduce the target modification is removed by the
combination of I-SceI cleavage and Red recombination
through sequence duplications that were previously
introduced into the targeting vector [34].
Each method has advantages and disadvantages
depending on the potential applications of the EBV
BAC mutants. The linear targeting vectors can be
designed quickly and construction of the mutants
usually takes only a few days. However, even after elimi-
nation of the antibiotic resistance cassette, prokaryotic
sequences will usually be left behind. Most of the time,
these foreign sequences have no influence on viral gene
expression and they can even be advantageous in the
case of mutants that carry a complete deletion of a
g i v e ng e n ea st h e yk e e pt h et o t a ls i z eo ft h ev i r u sc o n -
stant. However, if more subtle mutations are required,
circular targeting vectors, galK selection or two-step
kana AB
F-factor
AB
+
AB
AB
frt frt
frt
flp
recombinase kanamycin
selection
EBV BAC EBV BAC EBV BAC
mutant 
+kana
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recombination
goi
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F-factor F-factor
Figure 2 EBV BAC mutagenesis in E. coli. Recombination with linearized targeting vectors. This method allows deletions or exchanges of
genetic material from the EBV DNA against foreign sequences. The latter can be mutated versions of an EBV gene, or DNA fragments of cellular
or bacterial origin. Selection of successfully recombined BACs requires the introduction of an antibiotic resistance cassette flanked by Flp-
recombinase target (FRT) sites. Transient introduction of the FLP recombinase allows excision of the antibiotic resistance cassette.
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Figure 3 Chromosomal building in E. coli. Recombination with circular targeting vectors. Chromosomal building is one of several techniques
that allow seamless mutagenesis. It is based on a targeting vector that carries: i) an antibiotic resistance cassette e.g. ampicillin (amp); ii) the
sequence to be introduced into the EBV-BAC (represented by the grey shading and star) flanked by EBV-specific sequences (designated as A and
B on the EBV BAC and A’ and B’ on the targeting vector) that will determine its site of insertion; iii) the gene that encodes the lacZ enzyme; and
iv) a temperature-sensitive origin of replication that is operative only at 30°C. The targeting vector is introduced into E.coli cells that carry the
EBV BAC. Recombination between both prokaryotic episomes is performed by a recA recombinase present on the targeting vector, whose
expression is driven by an arabinose-inducible promoter. Homologous recombination can be initiated anywhere within the regions of homology
(indicated by an arrow). The antibiotic resistance cassettes present on the targeting vector (amp) and on the EBV BAC (cam) allow the selection
of co-integrates, which are a fusion vector comprising the targeting vector and the EBV BAC. Propagation at 42°C (non-permissive temperature)
forces the loss of free targeting vectors. A second round of recombination resolves the co-integrates and reconstitutes both the EBV BAC and
the targeting vector. Depending on which flanking region initiates resolution of the co-integrate, a recombinant EBV BAC containing either the
foreign sequence (a) or the wild type (b) will be generated. Reconstituted targeting vectors are eliminated by culture at non-permissive
temperature. Candidate clones are assessed for their sensitivity to ampicillin and expression of the lacZ gene. LacZ-negative and ampicillin-
sensitive clones, indicative of reconstituted EBV BACs, are then submitted to restriction enzyme analysis, colony PCR or any other appropriate
technique. goi: gene of interest.
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ods of choice.
Random transposon mutagenesis has been used to
generate libraries of CMV or PrV mutants [19,35]. The
relative inefficiency with which EBV BACs can be pack-
aged into infectious viruses and selected for a particular
phenotypic trait among a complete mutant library ren-
ders this approach perhaps less attractive for EBV.
Revertant generation
By definition, a revertant is the reversion of a mutant
virus to the wild type configuration. Revertant viruses
are often used as controls to demonstrate that the phe-
notypes of mutant viruses can be attributed to a specific
mutation or gene deletion, and not to any secondary
mutations that may have occurred elsewhere in the gen-
ome during mutagenesis. Subsequently, a revertant
should be absolutely identical to the recombinant wild
type sequence and must not carry any foreign
sequences. Therefore, typically, the chromosomal build-
ing technique, galK selection or Red recombination
coupled to I-SceI cleavage will be used for generating
revertants. The method for generating revertants is
identical to the one previously described, except that in
this case the mutant is used as the reference genome
and the wild type sequence is introduced into the tar-
geting vector. Alternatively, allelic exchange following
conjugation between bacterial cells that contain the
mutated HV-BAC and other bacterial cells that contain
the wild type allele cloned onto a vector that permits
conjugation has also been successfully used to construct
revertants [19].
Producer cell lines
Once the mutant and the revertant genomes have been
obtained, they can be stably introduced, using various
methods, into the cell line to be used as a producer cell
line. This is most commonly achieved by direct transfec-
tion or co-culture between the bacterial cells that carry
the EBV BAC and the eukaryotic cells to be transfected
[23]. After selection with an antibiotic that is toxic to
EBV BAC-negative eukaryotic cells, resistant clones are
then tested for their ability to support the lytic cycle.
We select clones that carry intact EBV BAC episomes
and that produce viral titers in excess of 10
7 genome
equivalents per ml supernatant, as assessed by a qPCR-
based method (please refer to the control section below
for more detail).
Controls
With the increasing use of EBV recombinants, we feel
that it is important to expand on the issue of appropri-
ate controls. Passaging of the EBV genome and intro-
duction of mutations via homologous recombination
can be accompanied by multiple unintended secondary
mutations. This can include gross rearrangements such
as a reduction in the number of repeats (BamHI-W
repeats, terminal repeats, NotI repeats, etc.) or massive
deletions in the viral genome that can be easily detected
by restriction enzyme analysis of EBV recombinant plas-
mid preparations, but can also include point mutations
that can be more difficult to identify (Figure 4). There-
fore, it is important to assess the structure of EBV
recombinants not only during construction of the
mutant, but also after establishment of the producer cell
line. To this aim, EBV episomes present in the producer
cell line can be extracted and re-introduced in E.coli to
be re-analyzed by restriction enzyme analysis. As EBV
producer cell lines are monoclonal in origin and carry
on average 5 to 10 episomes, analysis of 5 to 10 bacter-
ial clones from each putative EBV producer cell line will
give a good overview of the quality of the producer cell
line. Altogether, we find that up to two-thirds of produ-
cer cell lines carry a mixture of intact and defective EBV
genomes (Figure 4).
Alpha-and betaherpesvirologists have been using
revertants and trans-complementation as controls for
decades. Revertants use the mutant genomes as a basis
to reconstitute the wild type sequence to ensure that no
additional mutations were introduced during mutagen-
esis. Indeed, if a mutant were to carry crippling muta-
tions in addition to the mutation of interest, the
revertant will not recover all wild type properties. Simi-
larly, trans-complementation consists of transient or
stable introduction of an expression plasmid encoding
the genetic element previously deleted and in most
cases it is a better control than a revertant. Indeed, viral
gene loci frequently carry multiple genes that partially
overlap and inactivation of one gene might disrupt
expression of other genes in immediate proximity.
Whilst in that case a revertant will correct the pheno-
type and therefore overlook the mutant’sc o n s t r u c t i o n
flaws, trans-complementation will not. In principle, per-
fect trans-complementation, i.e. complete reversion of
the mutant’s phenotypic traits upon reintroduction of
the missing genetic element, renders the construction of
a revertant dispensable. However, there are many cases
where trans-complementation is not possible; deletion
of a cis-element such as an origin of replication
obviously cannot be complemented. In addition, some
cells, e.g. primary B cells or LCLs cannot be efficiently
targeted by trans-complementation. EBV-derived vectors
that can be replicated and packaged or lentiviruses have
been previously used, but these also target B cells with
limited efficiently.
Several strategies have been developed in an attempt
to circumvent these limitations. Complementation vec-
tors that carry a drug-resistance gene and therefore
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Alternatively, LCLs can be transfected with complemen-
tation plasmids that also encode a truncated nerve
growth factor receptor (NGFR). Transfected cells can
then be purified using NGFR-specific antibodies [36,37].
Another possibility is to target B cells with a retrovirus
or an expression plasmid that encodes a fluorescent pro-
tein in addition to the gene used for complementation.
This would enable the transfected cells to be FACS-
sorted. Issues regarding the level of expression and tim-
ing of trans-complementation compared to wild type
gene expression provide an additional layer of complex-
ity. To say that gene regulation of the viral genome or
of an expression plasmid frequently differ is stating the
obvious. We have previously encountered this problem
when working with viral enzymes whose powerful
effects require finely tuned ex p r e s s i o nb o t hi ni n t e n s i t y
and timing [38]. The use of conditional systems (e.g.
Figure 4 Assessing the EBV BAC structure by restriction enzyme analysis. (A) Schematic overview of the EBV genome indicating the
position of the various DNA repeats. IR: internal repeats, TR: terminal repeats, FR: family of repeats. (B) Restriction analysis of EBV BACs stably
transfected into 293 cells. The left panel shows the predicted position of viral fragments after BamHI restriction. The right panel shows actual
examples of abnormal EBV BACs rescued from producer cell lines. One EBV BAC carried fewer NotI repeats than the control (lane 1, purple
arrow), another EBV BAC contained fewer TRs but more FRs (lane 2 red and green arrows, respectively), and a third recombinant carried fewer
BamHI-W repeats (lane 5, blue arrow). Examples of large deletions (lane 3 and 4) are also shown. All of these abnormal clones were discarded.
wt: wild type.
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versatile solution to these problems [39]. In all of these
cases, revertants become indispensable as controls.
Recent technological developments might change this
view. The availability of high-throughput sequencing
platforms in a growing number of research centers ren-
ders it now possible to obtain the complete viral gen-
ome sequence for large viruses such as EBV. Therefore,
the presence of adventitious mutations in mutants
could, in principle, be excluded. However, we have used
this technology to sequence purified EBV BACs and
found that sequencing of GC-rich sequences, in particu-
lar within the repeats that abound in the EBV genome,
is difficult (unpublished data). As a result, seamless
assembly of the complete sequence was not possible and
we could not exclude the presence of small deletions or
unintended rearrangements. In addition, deep sequen-
cing typically results in multiple reads of the same DNA
segment, some of which will carry point mutations. Dis-
tinguishing sequencing mistakes from genuine muta-
tions present in only a subset of the sequenced EBV
BAC molecules also proved impossible. Therefore, we
feel that the construction of revertants will continue to
be an important control.
Tiling arrays that consist of oligonucleotides spanning
the entire BAC sequence have been used to detect
mutations in HV BACs. In this case, hybridization of
wild type viral DNA is used as a reference sample and
allows direct comparison with BAC DNA, as recently
shown for rhesus rhadinovirus BAC [18].
One frequently heard criticism about the use of BAC-
based mutants, as compared to mutants constructed in
eukaryotic cells, is that the transfected DNA has a dif-
ferent methylation pattern. Indeed, HV BACs carry a
bacterial epigenetic signature, whereas mutant viruses
constructed in eukaryotic cells obviously maintain a
eukaryotic methylation pattern. However, for generation
of mutants in eukaryotic systems, new rounds of infec-
tion are required and it has been shown that EBV DNA
in infectious particles is unmethylated. Therefore, cells
to be used as producer cell lines become infected with
unmethylated genomes [40,41]. The only potential pro-
blem of EBV BACs is therefore that they initially carry
bacterial-type methylation residues. However, these will
be lost after a few cell divisions and are unlikely to
adversely interfere with viral functions. The observation
that alpha-and betaherpesvirus BACs efficiently initiate
virus production after transfection into a permissive cell
line certainly supports this view [11,13,26]. Another
important aspect, which was alluded to in the previous
section and which may also be related to methylation
patterns, is the ability of a cell clone to support the EBV
life cycle. As already mentioned, only a minority of EBV
BAC-containing clones will produce high titers (i.e. as
high as marmoset LCLs such as B95.8). However, many
of these will initiate replication and progress into the
lytic replication phase up to a variable stage but will not
complete it. Does abortive lytic replication stem from a
defect limited to the late stages of lytic replication, or
will this defect affect replication altogether? In the first
case, such a producer cell line would probably be valid
for the study of early replication events, however, in the
second case it runs the risk of delivering artefactual
results. There is currently no experimental evidence to
distinguish between these alternatives, however, given
these possibilities we feel that it is probably safer to
restrict studies to producer clones that generate virus
titers in the range of 10
7 genome equivalents/ml upon
induction. In the case of viruses in which a mutation
that impairs replication has been purposefully intro-
duced, these titers should be achieved after complemen-
tation with the deleted genetic element.
Applications
EBV Infection
The genetic analysis of EBV functions required for viral
infection has mainly been performed with mutants gen-
erated by conventional construction methods. Two pub-
lished studies made use of EBV BAC mutants in which
either the BLLF1 or BALF4 gene, coding for gp350 or
gp110, respectively, were deleted [42,43]. A virus that
lacks gp350 infects primary B cells less efficiently than
its wild type counterparts, but the virus nevertheless
remains infectious. Gp350 was thought to function pri-
marily function in B cell binding. However, gp350
mutant viruses maintain their ability to bind to B cells,
although less efficiently, relative to controls, suggesting
that additional viral ligands may contribute to B cell
binding. To determine whether gp350’sf u n c t i o n sa r e
restricted to binding, we compared infection rates
between ΔBLLF1 viruses that had or had not been com-
plemented with an antibody chimera that comprises the
gp350 transmembrane domain and an antibody directed
against CD21, EBV’s main receptor on B cells [44].
Whilst ΔBLLF1 viruses that expressed an antibody
against CD21 at their surface bound to B cells as effi-
ciently as ΔBLLF1 complemented with the entire gp350
protein, they were not as efficient in infecting B cells
[44]. We concluded that gp350 serves additional func-
tions than merely binding to its target cells.
EBV Replication
EBV replication requires sequential steps of viral protein
synthesis. The immediate early proteins that initiate this
process are transactivators that stimulate the synthesis
of early and late proteins involved in DNA replication
and construction of the infectious viruses. Two transac-
tivators, Zta and Rta, encoded by BZLF1 and BRLF1
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[45,46]. Studies using mutants that lack either Zta or
Rta showed that both proteins are required for virus
production [47]. Their functions are therefore not
redundant; Zta and Rta were found to preferentially
activate different early and late proteins. Furthermore,
the 293/ΔBZLF1 producer cell line has proven to be
very useful for a detailed genetic analysis of BZLF1 func-
tions [48-56]. Indeed, this virus producer cell line can be
efficiently transfected and the endogenous BZLF1 gene
does not interfere with transfected Zta mutant proteins.
More generally, the 293/ΔBZLF1 producer cell line has
been used as a completely replication-negative EBV
infected cell line and LCLs immortalized with ΔBZLF1
viruses provide a helpful control in the analysis of T
cells directed against lytic proteins [37,57,58].
EBV-mediated transformation
The EBV latent genes have been extensively studied
using overlapping cosmid technology. However, EBNA1
has not been the focus of these types of investigations.
One reason for that is that EBNA1 is required for EBV
maintenance in latently infected B cells. BAC technology
allowed the construction of a 293 cell line expressing
EBNA1 in trans, into which the EBNA1-negative mutant
can be transfected [59]. The EBNA1 mutant virus
proved to be 10
4 times less infectious than its wild type
counterparts. Indeed, EBV could persist in B cells only
through integration of the viral DNA within the cellular
genome, provided that the integration did not impede
latent gene protein synthesis. Furthermore, the 293/
ΔEBNA1 producer cell line was useful for investigating
the role of EBNA1 as a transactivator of other latent
proteins [60].
Although the active latency phase of EBV infection is
classically thought to be mediated by the latent genes, B
cells exposed to viruses devoid of BALF1 and BHRF1
died of apoptosis immediately after infection [61].
Therefore, the concept of latent genes, or rather of viral
genes serving dual lytic and latent functions could be
extended to these two viral bcl2 homologs. Importantly,
viruses that lacked only one of these genes were indis-
tinguishable from wild type viruses, suggesting either
that BALF1 and BHRF1 interfere with the cell apoptosis
programme in two different ways, or that a high expres-
sion level of anti-apoptotic proteins is required to coun-
teract cell death [61].
Immune evasion
In the last five years, a number of viral proteins were
found to block immune recognition of viral proteins
during lytic replication (BGLF5, BZLF2, BILF1, BNLF2a)
[37,58,62-64]. The direct contribution of BNLF2a in
immune evasion was proven using a EBV BAC devoid
of the BNLF2a gene [37]. This recombinant virus elicits
a stronger MHC class I T cell response against viral
lytic genes than wild type viruses.
VLPs as a source of viral antigen
Virus-like particles (VLP) have been successfully used as
preventative vaccines against Hepatitis B viruses or
Papillomaviruses [65,66]. Supernatants from induced
EBV producer lines also contain defective virions includ-
ing VLP that lack viral DNA and light particles (LP) that
lack both viral DNA and capsids. These abnormal infec-
tious particles also represent minor sub-populations in
supernatants from cultures infected with HSV or CMV
[67,68]. We previously reported the phenotypic traits of
an EBV mutant devoid of terminal repeats (TR) that
produces large amounts of VLP and LP, but no intact
virions. Supernatants from induced 293/ΔTR producer
cells were found to elicit a potent CD4+ cytotoxic T cell
response against various components of the mature vir-
ions [69,70]. EBV VLP could therefore be used as a
source of antigens in T cell therapy protocols or even as
a preventative vaccine. Whether the immune response
elicited by VLP/LP would be sufficient to afford protec-
tive immunity against wild type virus infection in vivo
cannot be determined using the data currently available.
Future directions
Although there are multiple ways in which the BAC sys-
tem could be improved, some areas appear to be in par-
ticular need of improvement. In contrast to alpha and
beta HV, the number of cloned EBV strains is restricted
to only B95.8 and Akata. The reason for this state of
a f f a i r si so b v i o u s ;t h eB A Cs y s t e mr e q u i r e ss u c c e s s f u l
recombination in eukaryotic cells, a process with low
efficiency. In addition, introduction of the F-plasmid in
EBV-positive cell lines is sometimes difficult, particularly
in human LCLs. As establishment of LCLs is the easiest
way to expand EBV, the number of viral strains amen-
able to cloning is restricted. Nevertheless, we feel that
the availability of more EBV BACs would substantially
increase the power of this technology.
Several HV BACs have been improved to include a
mechanism that enables removal of the BAC from the
recombinant virus. One of these ‘auto-excisable’ systems
consists of BACs flanked by cre recombinase target
sites. For example, this system was used to co-infect
Vero cells with the HSV-1 BAC and with an adenovirus
vector that encodes the cre recombinase [71]. Another
system utilizes endonuclease I-SceI cleavage and intra-
molecular Red recombination of inverted sequence
duplications adjoining the prokaryotic vector backbone
[34] and allows the markerless removal of all vector
sequences upon virus reconstitution in eukaryotic cells.
This system was applied to the analysis of an essential
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sons to think that these elegant experimental systems
cannot be directly adapted to EBV BACs. For reasons
previously stated, producer cell lines must be kept
under antibiotic selection to avoid the rapid loss of the
EBV episomes. Indeed, 293 cells are not dependent on
EBV for growth and, although infected cells express
EBNA1, they will lose episomes with time if the selec-
tion pressure is eased. Thus, it is currently impossible to
excise the F-plasmid from EBV producer cells. It would
therefore be necessary to activate the cre recombinase
immediately before the onset of replication. This would
require targeting every single replicating cell of the pro-
ducer cell line, e.g. with an adenoviral vector carrying
the cre recombinase, and then also require 100% effi-
ciency of recombination and no interference with the
replication process. Another drawback of this kind of
strategy is that phenotypic markers such as GFP are lost
in the process.
Another alternative would be to clone the BAC within
EBV repeats, as recently suggested for rhadinoviruses
[73]. Upon induction of lytic replication, the BAC back-
bone is eliminated as a result of recombination between
the two flanking terminal repeats.
Finally, and perhaps most importantly, it is necessary
to improve the quality of producer cell lines, in terms of
generation time, level of virus production, and stability
of the viral genome. Transfection of EBV DNA into a
large panel of cell lines might help in identifying cells
that show a high degree of permissivity as was pre-
viously observed for HEK293 or 293T cells. Steady
improvements in our knowledge of the mechanisms that
negatively control lytic replication might also have the
very prosaic benefit of potentiating virus production.
Conclusions
BAC recombinant technology has opened completely
new areas of research for herpesviruses in general, but
the benefits were particularly tangible for the study of
gammaherpesviruses whose natural tendency to enter
latency renders the study of infection and lytic replica-
tion difficult. This system has proven highly versatile
and has virtually no limitations in terms of the genetic
manipulation that it enables. There are now several sys-
tems available and the technology is being used by a
growing number of laboratories. Nevertheless, construc-
tion of recombinant viruses remains tedious and time
consuming. In particular, construction of a good produ-
cer cell line sometimes requires screening a large num-
ber of clones. In addition, it remains essential to
perform all the necessary controls, e.g. the construction
of revertants, which can be more demanding than the
generation of the mutant itself. Future developments,
some of which are already emerging, include the
development of cell lines that efficiently support EBV
lytic replication and do not lose this ability over time,
cloning of more EBV strains, e.g. a type 2 EBV strain,
and the design of recombinants in which the BAC back-
bone is auto-excisable.
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